Loading company…
Pretzel Therapeutics develops treatments for mitochondrial dysfunction.
Pretzel Therapeutics develops therapies targeting mitochondrial dysfunction, including genome correction, gene expression modulation and mitochondrial quality control. The company was founded by Michal Minczuk, Claes Gustafsson, Paul Thurk and Nils-Göran Larsson. In September 2022, it raised USD 72.5 million in Series A funding led by ARCH Venture Partners and Mubadala Capital, with several other investors participating. The funding will support preclinical development and team growth.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in